Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.

ABSTRACT: Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

SUBMITTER: Wakabayashi G 

PROVIDER: S-EPMC6894306 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature